Programme

Tuesday October 5th

14.00 - 18.00 Registration
18.00 - 21.00 Welcome reception

Wednesday October 6th

Main Lecture Theatre

9.00 - 9.20 Welcome

Inflammation and Fibrin Regulation

Chair:
Jeremy Thompson (London, UK)
Jack Gauldie (Hamilton, Canada)

9.20 - 10.00 S Idell (Tyler, USA)
Post-translational regulation of the urokinase receptor by mesothelial and mesothelioma cells [1]

10.00 - 10.40 L Holmdahl (Gteborg, Sweden)
Proteases in peritoneal tissue repair [2]

10.40 - 11.10 Coffee

Chair:
Stephen Idell (Tyler, USA)
Lena Holmdahl (Gteborg, Sweden)

11.10 - 11.50 T Kooistra (Rotterdam, Netherlands)
Peritoneal Fibrinolysis [3]

11.50 - 12.05 GJ Bellingan, H Cooksley, F Chua, GJ Laurent, SE Mutsaers (London, UK)
Macrophage adhesion to mesothelial cells during the resolution of acute and chronic peritoneal inflammation [4]

12.05 - 12.20 TS Wilkinson, AS Williams, U Janssen, U Kunter, J Floege, N Topley (Cardiff, UK)
The role of interleukin-6 (IL-6) in peritoneal inflammation: Control of neutrophil influx during peritoneal inflammation by a chemokine dependent mechanism [5] NIA

12.20 - 12.35 CM Hoff, KL Inman, D Piscopo, TR Shockley (McGaw Park, USA)
Mesothelial cells genetically modified to produce IL-10 inhibit macrophage production of proinflammatory cytokines [6]

12.35 - 14.00 Lunch
**Serosal repair**

Chair: Stephen Albelda (Philadelphia, USA)
PAX

14.00 - 14.40 E Hay (Boston, USA)  
Epithelial-mesenchymal transformation [7]

14.40 - 15.20 PJ Margetts, TM Galt, M Kolb, J Gauldie (Hamilton, Canada)  
The effect of transient overexpression of transforming growth factor beta on the peritoneal membrane [8]

15.20 - 15.35 W Sendt, G Wolff-Vorbeck, BU Specht, U Schöffel (Freiburg, Germany)  
Co-cultured human mesothelial and endothelial cells as an access for studying the physiology of the peritoneal membrane [9]

15.35 - 16.05 Tea

Chair: Agnes Kane (Providence, USA)
PAX

16.05 - 16.45 A Raftery (London, UK)  
Peritoneal repair: the early days [10]

16.45 - 17.00 S Mutsaers, D Whitaker, JM Papadimitriou (London, UK)  
Mesothelial regeneration is not dependent on subserosal cells [11]

17.00 - 17.15 T Al-Mishlab, SE Herrick, GJ Laurent, SE Mutsaers (London, UK)  
Phenotypic changes are not demonstrated in submesothelial cells during serosal healing [12] NIA

17.15 - 17.30 AJ Foley - Comer, SE Herrick, T Al-Mishlab, GJ Laurent, SE Mutsaers (London, UK)  
Di-I labelled cultured mesothelial cells are incorporated into regenerating mesothelium: Identification of putative progenitor cells [13] NIA

18.30 - 23.00 Cocktail reception, dinner and Monte Carlo evening
<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker(s)</th>
<th>Title</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>9.00</td>
<td>V Rush (New York, USA)</td>
<td>The IMIG staging system: How relevant is it? [M1]</td>
<td>Library</td>
</tr>
<tr>
<td>10.20</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10.50</td>
<td>SM Albelda (Philadelphia, USA)</td>
<td>Gene therapy for benign and malignant disorders [M3]</td>
<td></td>
</tr>
<tr>
<td>11.30</td>
<td>DH Sterman, A Recio, K Molnar-Kimber, K Amin, J Hughes, A Alavi, M Lanuti, LA Litzky, SM Albelda, LR Kaiser (Philadelphia, USA)</td>
<td>Herpes simplex virus thymidine kinase (HSVtk) gene thraputilizing an E1/E4-deleted adenoviral vestor: Preliminary results of a phase I clinical trial for pleural mesothelioma [M4]</td>
<td></td>
</tr>
<tr>
<td>11.45</td>
<td>JPC Steele, MT Evans, J Shamash, NH Gower, MD Tischkowitz, RM Rudd (London, UK)</td>
<td>Effective palliation of malignant pleural mesothelioma (MPM): A phase II study of vinorelbine [M5] NIA</td>
<td></td>
</tr>
<tr>
<td>12.00</td>
<td>C Robinson, M Callow, S Stevenson, BWS Robinson, R Lake, (Perth, Australia)</td>
<td>Antigens associated with malignant mesothelioma [M6]</td>
<td></td>
</tr>
<tr>
<td>12.15</td>
<td>C Vivo, F Levy, J Fleury-Feith, K Leroy, L Kheuang, I Monnet, D Chopin, MC Jaurand (Crteil, France)</td>
<td>Cell cycle analysis in interferon gamma (IFN) treated human mesothelioma cell lines (HMCLs) [M7] NIA</td>
<td></td>
</tr>
<tr>
<td>14.00</td>
<td>K Dobra, X Sun, A Hjerpe (Stockholm, Sweden)</td>
<td>Differences in gene expression between epithelial and fibrous mesothelioma cells [M8]</td>
<td></td>
</tr>
<tr>
<td>14.15</td>
<td>L Mutti, PG Betta, L Strizzi, R Libener, G Tassi, R Puntoni, A Procopio (Vercelli, Italy)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
(Simian virus 40 (SV-40) - like DNA sequences, histology and survival in pleural malignant mesothelioma [M9]

14.30 - 15.45  

**Poster discussion**

**JG Edwards**, J MvLaren, RA Walker, DA Waller, KJ O’Byrne *(Leicester, UK)*
Evaluation of matrix metalloproteinase activity in malignant mesothelioma and benign pleura [P1]

**P Harvey**, D Edwards, R Warn *(Norwich, UK)*
Expression of matrix metalloproteinases in mesothelioma cell lines and their regulation by hepatocyte growth factor/scatter factor [P2]

**R Foddis**, A Vivaldi, G Guglielmi, V Gattini, R Buselli, G Sensales, EM Giancia, A Powers, F Ottenga, A Cristaudo *(Pisa, Italy)*
Study about SV 40-sequences in paraffin embedded mesothelioma samples [P3]

**K Takabe**, K Tsuchiya, T Fukuoka, Y Kodaira, Y Shinohara, S Usui, M Inagaki, N Funakoshi, K Suzuki, H Akabane, H Ishiwata, H Miura, K Horita, NiNase *(Ibaraki, Japan)*
SV-40-like DNA sequences in malignant mesothelioma in Japan [P4]

**S Orecchia**, R Libener, G Gaudino, L Mutti, **PG Betta** *(Alessandria, Italy)*
The expression and cellular location of E- and N-cadherins in malignant mesothelioma [P5]

**MT Valle**, R Libener, F Mignone, PG Betta, G Gaudino, A Procipo, L Strizzi, R Guida, **L Mutti** *(Vercelli, Italy)*
Transforming growth factor β (TGFβ)- released by PPD-presenting malignant mesothelioma cells (MMC) inhibits IFN synthesis by an anti-PPD CD4 T cell clone (TCC) [P6]

**K Amin**, A Kallarakal, DH Sterman, RL Kaiser, DM Jacobowitz, SM Albelda *(Philadelphia, USA)*
The regulation of the mouse calretinin promoter in mesothelioma cells [P7]

**V Ascoli**, C Carnovale Scalzo, F Nardi, D Falzetti, C Mecucci *(Rome, Italy)*
Familial aggregation of malignant mesothelioma: Five affected in one family with cancer history. Is there a genetic predisposition? [P8]

**CM Hoff**, D Piscopo, KL Inman, TR Shockley *(McGaw Park, USA)*
Adenoavirus mediated gene transfer to the peritoneal cavity [P9]
Y Inoue, T Nakano, M Miyake, A Tonomura, S Iida, N Togawa, T Hada (Hyogo, Japan)
Soluble CD44 and its immuno-histochemical expression in patients with malignant pleural mesothelioma [P10]

R Hbner, E Van Marck (Wilrijk, Belgium)
Detection of polyomavirus DNA in malignant pleural mesothelioma from Belgian patients [P11]

JPJJ Hegmans, H Kuipers, K Radosevic, S Burgers, HC Hoogsteden, J-B Prins (Rotterdam, Netherlands)
Isolation of antibodies from a semi-synthetic phage-antibody-display library to mesothelioma specific cell surface molecules [P12]

FM Kogan, SA Berzin, NA Tomilova (Ekaterinburg, Russian Federation)
Mesothelioma of pleura and chrysotile asbestos exposure [P13]

JG Edwards, JN Leverment, TJ Spyt, DA Waller, KJ O’Byrne (Leicester, UK)
Ten years of malignant mesothelioma in Leicester: Prognostic factors [P14]

JG Edwards, G Cox, RA Walker, DA Waller, KJ O’Byrne (Leicester, UK)
Increased chalkley microvessel counts are related to platelet count and convey poor prognosis in malignant mesothelioma [P15]

G Hillerdal, M Metintas, E Rasmussen, S Metintas (Stockholm, Sweden)
Erionite exposure: High mesothelioma rate despite lack of benign pleural lesions [P16]

N Togawa, T Nakano, Y Inoue, S Iida, T Atsusi, M Miyake, K Hada (Hyogo, Japan)
Soluble FAS (sFas) and FAS ligand (sFasL) in patients with malignant pleural mesothelioma [P17]

T Ollikainen, A Knuuttila, S Suhonen, A Jekunen, K Mattson, K Linnainmaa (Helsinki, Finland)
In vitro sensitivity of malignant mesothelioma cell lines to four new chemotherapeutic agents [P18]

A Knuuttila, T Ollikainen, A Jekunen, M Halme, K Linnainmaa, K Mattson (Helsinki, Finland)
Docetaxel and irinotecan (CPT-11) for malignant mesothelioma [P19]

E Kettunen, W El-Rifai, A-M Niissin, T Ollikainen, M Taavitsainen, K Linnainmaa, S Knuutila (Helsinki, Finland)
cDNA array study of gene expression profiles in malignant mesothelioma cell lines [P20]

15.45 - 16.05  Tea

Chair:  Marie-Claude Jaurand (Crteil, France)
        Anders Hjerpe (Stockholm, Sweden)

16.05 - 16.20  VC Broaddus, W Liu, GD Rosen (San Francisco, USA)
              TNF-related apoptosis-inducing ligand can induce apoptosis in mesothelioma cell lines [M10]

16.20 - 16.35  SP Faux, CE Houghton, A Hubbard, G Patrick (Leicester, UK)
              Expression of epidermal growth factor-receptor (EGF-R) in rat pleural mesothelial cells correlates with fibre carcinogenicity [M11]

16.25 - 16.50  E Kagan, S Tanaka, N Choe, A Iwagaki, J Zhang, DR Hemenway (Burlington, USA)
              Role of MCP-1 and mesothelial-leukocyte adhesion an asbestos-induced pleural injury [M12]

16.50 - 17.05  JG Edwards, SP Faux, RA Walker, DA Waller, KJ O’Byrne (Leicester, UK)
              Cyclo-oxygenase-2 expression in malignant mesothelioma (MM) [M13]

17.05 - 17.20  VM Williams, NH de Klerk, KD Wolanski, D Whitaker, KB Shilkin, AW Musk (Perth, Australia)
              Retained pulmonary mineral fibre profile and risk of malignant mesothelioma in Western Australia [M14]

17.20 - 17.35  B Nisman, J Lafair, N Heshing, O Lyass, C Reinus, T Peretz, V Barak (Jerusalem, Israel)
              Serum tumor markers in malignant pleural mesothelioma [M15]

18.45  Bus departs Stoke Rochford Hall for conference banquet

19.30 - 23.15  Conference banquet (The Sheriff’s Lodge)

23.15  Bus returns to Stoke Rochford Hall
<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker(s)</th>
<th>Title</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>9.55 - 10.10</td>
<td>J Leigh (Sydney, Australia)</td>
<td>Malignant mesothelioma in Australia (1945-1999) [M17]</td>
<td>Main conference Hall</td>
</tr>
<tr>
<td>10.10 - 10.25</td>
<td>BW Case, V Roggli, A Churg, M Camus, J Siemiatycki (Montreal, Canada)</td>
<td>Pathology validation and asbestos exposure for female pleural peritoneal malignancy in Quebec, Canada [M18]</td>
<td>Main conference Hall</td>
</tr>
<tr>
<td>10.25 - 10.45</td>
<td></td>
<td>Coffee</td>
<td></td>
</tr>
<tr>
<td>11.40 - 11.55</td>
<td>CA Vaslet, NJ Messier, AB Kane (Providence, USA)</td>
<td>Inactivation of p16(^{INK4a}), p15(^{INK4b}) and p19(^{ARF}) in murine mesothelioma cell lines [M21]</td>
<td>Main conference Hall</td>
</tr>
<tr>
<td>11.55 - 12.35</td>
<td>A Berns (Amsterdam, Netherlands)</td>
<td>The design of specific mouse tumour models using conditional knock-out strategies [M22]</td>
<td>Main conference Hall</td>
</tr>
<tr>
<td>12.35 - 12.45</td>
<td></td>
<td>Committee Meeting Announcements</td>
<td>Main conference Hall</td>
</tr>
<tr>
<td>12.45 - 14.00</td>
<td></td>
<td>Lunch</td>
<td>Main conference Hall</td>
</tr>
<tr>
<td>14.40 - 14.55</td>
<td>AP Chahinian, H Gluck (New York, USA)</td>
<td></td>
<td>Main conference Hall</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td></td>
<td></td>
</tr>
<tr>
<td>--------</td>
<td>-------------------------------------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>14.55 - 15.10</td>
<td><strong>T Nakano, Y Inoue, A Tonomura, N Togawa, S Iida, M Miyake, N Togawa, T Hada (Hyogo, Japan)</strong>&lt;br&gt;Irinotecan (CPT-11) and Doxorubicin (ADR) in the treatment of patients with malignant pleural mesothelioma: A pilot clinical trial [M26]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15.25 - 15.40</td>
<td><strong>B Castagneto, M Botta, G Grecchi, D Grosso, M Merlano, C Zanon, S Zai, A Mussa (Monferrato, Italy)</strong>&lt;br&gt;Thoracic stop-flow in pleural mesothelioma: A dose-finding study [M28]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15.40 - 15.55</td>
<td><strong>JG Edwards, A Rengarajan, DA Waller (Leicester, UK)</strong>&lt;br&gt;A “one-stop” protocol of palliative debulking surgery for malignant mesothelioma gives lasting symptom relief [M29]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15.55 - 16.05</td>
<td>Closing remarks</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16.05 - 16.35</td>
<td><strong>Tea</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>